LSL Pharma Group Announces its Participation in the "2024 Bloom Burton & Co. Healthcare Investor Conference "
BOUCHERVILLE, Quebec, , April 09, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC (TSXV: LSL) (the "Company" or "LSL Pharma"), a Canadian integrated pharmaceutical company, announced today that it will participate in the Bloom Burton & Co. Healthcare Investor Conference. Mr. Roberge, President and CEO, will make a presentation on April 17 at 4:00 p.m. EST, and will be available for one-on-one meetings throughout the conference.
| Event: | 2024 Bloom Burton & Co. Healthcare Investor Conference | |
| Date: | April 16-17, 2024 | |
| Location: | Metro Toronto Convention Center, Ontario | |
| Presentation: | April 17 16:00 EST | |
To register for the 2024 Bloom Burton & Co. Healthcare Investor Conference, please follow this link.
ABOUT THE CONFERENCE
The Bloom Burton & Co. Healthcare Investor Conference brings together American, Canadian and international investors interested in the latest developments in the Canadian healthcare company. Participants will have the opportunity to obtain up-to-date information on leading Canadian public and private companies, through presentations and private meetings.
ABOUT LSL PHARMA GROUP INC.
LSL Pharma Group is an integrated Canadian pharmaceutical company specializing in the development, manufacturing and distribution of natural health products and supplements in solid dosage form, as well as high-quality sterile ophthalmic pharmaceuticals. For further information, please visit www.groupelslpharma.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements as defined under applicable Canadian securities legislation. Forward-looking statements can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "continue" or similar expressions. Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Corporation's ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, those identified in the Corporation's filings with Canadian securities regulatory authorities, such as legislative or regulatory developments, increased competition, technological change and general economic conditions. All forward-looking statements made herein should be read in conjunction with such documents.
Readers are cautioned not to place undue reliance on forward-looking statements. No assurance can be given that any of the events referred to in the forward-looking statements will transpire, and if any of them do, the actual results, performance or achievements of the Corporation may differ materially from those expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. The Corporation does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CONTACT : François Roberge, President and Chief Executive Officer Telephone: (514) 664-7700 E-mail: Investors@groupelslpharma.com
